Neurodegenerative Diseases - Alzheimer’s and Parkinson’s (Maple Valley)

Revolutionizing Neurodegenerative Disease Treatment with DNA Frequencies at Patient to Patient Neurodegenerative diseases such as Alzheimer’s and Parkinson’s pose significant challenges to both patients and healthcare providers. These conditions lead to the progressive degeneration of nerve cells, impairing cognitive and motor functions over time. While traditional treatments aim to slow progression, Patient to Patient offers a groundbreaking alternative through the use of DNA frequencies. By targeting specific genes and proteins associated with neurodegeneration, these frequencies provide an innovative, non-invasive approach to support cognitive health and potentially slow the decline in neurological function. Understanding Neurodegenerative Diseases Neurodegenerative diseases involve the deterioration of neurons, which are the building blocks of the nervous system. As these cells degenerate, the body loses vital functions, from memory and reasoning to motor control. Two of the most common neurodegenerative diseases are Alzheimer’s and Parkinson’s, both of which are linked to specific genetic mutations and protein misfolding. Alzheimer’s Disease: Targeting Key Genetic Markers Alzheimer’s disease is characterized by memory loss, cognitive decline, and the accumulation of amyloid plaques in the brain. By leveraging DNA frequencies, it is possible to target the key genes involved in Alzheimer’s: • PSEN1 (Presenilin 1): Mutations in this gene result in the production of amyloid-beta peptides, which clump together to form plaques in the brain. Frequencies aimed at PSEN1 may help slow plaque formation and protect neurons. • PSEN2 (Presenilin 2): Similar to PSEN1, mutations in PSEN2 are linked to early-onset Alzheimer’s. Frequencies directed at PSEN2 can help reduce the accumulation of toxic proteins and improve brain function. • ApoE4 (Apolipoprotein E4): ApoE4 is one of the strongest genetic risk factors for Alzheimer’s. Targeted frequencies for ApoE4 could support cholesterol regulation in the brain, minimizing the risk of amyloid plaque development. By focusing on these genetic markers, we can help mitigate the progression of Alzheimer’s by reducing amyloid buildup and protecting neural health. Parkinson’s Disease: Addressing Protein Misfolding Parkinson’s disease is characterized by tremors, rigidity, and bradykinesia (slowness of movement), stemming from the loss of dopamine-producing neurons. By using DNA frequencies, we can target: • SNCA (Alpha-Synuclein): Mutations in the SNCA gene are linked to the accumulation of alpha-synuclein protein aggregates. Frequencies targeting SNCA can help reduce these toxic aggregates and improve neural function. • LRRK2 (Leucine-Rich Repeat Kinase 2): Mutations in LRRK2 are associated with both familial and sporadic Parkinson’s cases. Frequencies directed at LRRK2 can help regulate protein folding and reduce the formation of harmful aggregates. By addressing these genetic components, we aim to support better motor function and slow the disease's progression. Experience the Future of Healing At Patient to Patient, we are dedicated to pioneering new, non-invasive treatments that can support cognitive health and slow the progression of neurodegenerative diseases. Our DNA frequency-based programs offer a promising alternative for those seeking innovative solutions to these challenging conditions. Explore the possibilities of DNA frequencies and embark on a journey to better neurological health with Patient to Patient. Contact us today to learn more and schedule your consultation. Patient to Patient, LLC 📞 (425) 202-6001